2616 — CStone Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- HK$7.77bn
- HK$6.36bn
- CNY269.58m
Brief: CStone Pharmaceuticals Enters Collaboration For Nofazinlimab In Mainland China
China's Zai Lab rises on product inclusion in National Reimbursement Drug List
Brief: CStone Pharmaceuticals Enters Licensing Agreement With Shenyang Sunshine Pharmaceutical
Brief: CStone Pharmaceuticals Announces Intention Of CEO To Increase Shareholding In Co
Brief: CStone Pharmaceuticals Posts Loss For Six Months RMB209.2 Million
Brief: Cstone Pharmaceuticals Receives GCP Inspection Notification From EMA For SUGEMALIMAB
Brief: Cstone Pharmaceuticals Says NMPA Approved Supplemental New Drug Application Of Gavreto
Brief: Cstone Pharmaceuticals Was Informed By CEO That He Purchased 460,000 Shares In Open Market
Brief: Cstone Pharmaceuticals says CEO Purchased A Total Of 501,000 Shares In Open Market
Brief: CStone Pharmaceuticals Says Blueprint Medicines Receives FDA Approval Of AYVAKIT
Brief: Cstone Pharmaceuticals Says CEO Purchased Total Of 629,000 Shares In Open Market
Brief: Cstone Pharmaceuticals Says Granted Exclusive License To Commercialize Sugemalimab Outside Of Greater China
Brief: Cstone Pharmaceuticals Says NMPA Accepted Supplemental Biologics License Application For Sugemalimab
Brief: Cstone Pharmaceuticals Loss For Year Was RMB902.7 Million
Over a dozen Chinese-based firms say they have minimal exposure to SVB (updated)
Six Hong Kong-listed firms say their deposits at SVB are immaterial
Brief: Cstone Pharmaceuticals Says NMPA Accepts Supplementary New Drug Application For Sugemalimab
Brief: Cstone Pharmaceuticals Says Acceptance Of Marketing Authorization Application By Ema For Sugemalimab
Kenneth Hitchner appointed Cydar Medical Chairman